| Literature DB >> 35637935 |
Marija Svetikienė1, Dainius Trybė2, Marius Strioga2, Jevgenija Vėželienė3, Viktoras Isajevas1, Radvilė Malickaitė4, Laimutė Jurgauskienė4, Donata Ringaitienė1, Mindaugas Šerpytis3, Jūratė Šipylaitė1.
Abstract
Background: Cardiac surgery provokes an intense inflammatory response that can cause an immunosuppressive state and adverse postoperative outcomes. We recently showed that postoperative immunonutrition with glutamine in "fragile" low-risk cardiac surgery patients was associated with a significantly increased level of CD3+ and CD4+ T cells. In order to clarify the biological relevance and clinical importance of these findings, we investigated whether an increase in the CD4+ T cell level was caused by changes in the systemic inflammatory response (caused by surgery or infection) and if it was associated with their activation status.Entities:
Keywords: CD4+; CD69+; CD8+; cardiac surgery; cytokine; glutamine; immunonutrition
Year: 2021 PMID: 35637935 PMCID: PMC9133614 DOI: 10.15388/Amed.2021.28.2.16
Source DB: PubMed Journal: Acta Med Litu ISSN: 1392-0138
Selection criteria
|
|
| Elective cardiac surgery with cardiopulmonary bypass (CPB): coronary artery bypass grafting (CABG); aortic valve replacement; mitral valve replacement; mitral valve repair; tricuspid valve repair; combined operations (CABG and valve surgery). |
|
|
| Preoperative: previous cardiac surgery; left ventricle ejection fraction < 40%; use of preoperative intra-aortic balloon pump (IABP); critical preoperative state; pulmonary artery mean pressure > 55 mmHg; diagnosis of infectious endocarditis; pacemaker. complicated intraoperative course (unplanned intervention or low cardiac output syndrome in the operating theatre: failure to wean from CPB, intraoperative insertion of IABP or infusion of two or more inotropic medications with a cumulative dose of 0.2 mcg/kg/min); surgery time > 6 h; unplanned intervention. disturbance of dietary rules. |
Baseline demographics and clinical characteristics of patients
| IN group | C group | p | |
|---|---|---|---|
|
| |||
| Age (years) | 68.3 ± 6.9 | 71.0 ± 5.4 | 0.112 |
| Sex: | |||
| Male, n (%) | 14 (51.9) | 14 (50.0) | 0.891 |
| Female, n (%) | 13 (48.1) | 14 (50.0) | |
| Body mass index (kg/m2) | 28.6 ± 5.1 | 27.8 ± 4.5 | 0.550 |
| Phase angle (0) | 5.2 [5.04–5.32] | 5.11 [4.72–5.30] | 0.117 |
|
| |||
| NYHA classification: | >0.05 | ||
| Class II, n (%) | 3 (11.1) | 0 (0) | |
| Class III, n (%) | 24 (88.9) | 28 (100.0) | |
| Class I and IV, n (%) | 0 (0) | 0 (0) | |
| ASA physical status | |||
| ASA III, n (%) | 27 (100.0) | 28 (100.0) | >0.05 |
| CCI | 3 [2.00–4.00] | 3 [3.00–3.75] | 0.570 |
| Arterial hypertension, n (%) | 23 (85.2) | 26 (92.9) | 0.362 |
| Renal failure, n (%) | 2 (7.4) | 1 (3.6) | 0.531 |
| Myocardial infarction, n (%) | 9 (33.3) | 5 (17.9) | 0.188 |
| Diabetes, n (%) | 7 (25.9) | 7 (25.0) | 0.937 |
|
| |||
| EuroScore II (%) | 1.97 ± 0.8 | 1.99 ± 0.8 | 0.918 |
| Operation type: | >0.05 | ||
| CABG, n (%) | 17 (63.0) | 18 (64.3) | |
| Aortic valve, n (%) | 4 (14.8) | 4 (14.3) | |
| Mitral valve, n (%) | 3 (11.1) | 1 (3.6) | |
| Tricuspid valve, n (%) | 1 (3.7) | 0 (0) | |
| Combined, n (%) | 3 (11.1) | 5 (17.8) | |
| Aortic cross-clamp time (min) | 75.5 ± 29.3 | 75.2 ± 25.4 | 0.966 |
| CPB time (min) | 112.6 ± 39.3 | 109.2 ± 34.2 | 0.735 |
| Operation time (min) | 257.4 ± 73.5 | 258.75 ± 62.4 | 0.944 |
NYHA – New York Heart Association; CABG – coronary artery bypass grafting; ASA – American Society of Anesthesiologists; CCI – Charlson comorbidity index
Mean value and standard deviation (mean ± SD); median and interquartile range (median [IQR]); p value
Pre- and postoperative immune cell indicators
| Preoperative | Postoperative | |||||
|---|---|---|---|---|---|---|
| IN group | C group | p | IN group | C group | p | |
| CD3+ T cells (*109/l) | 1.44 ± 0.61 | 1.15 ± 0.62 | 0.093 | 1.42 ± 0.49 | 1.12 ± 0.56 | 0.035 |
| CD4+ T cells (*109/l) | 0.95 ± 0.39 | 0.76 ± 0.41 | 0.091 | 1.02 ± 0.36 | 0.80 ± 0.43 | 0.048 |
| CD8+ T cells (*109/l) | 0.48 ± 0.28 | 0.38 ± 0.29 | 0.191 | 0.40 ± 0.21 | 0.30 ± 0.18 | 0.066 |
| CD4+CD69+ T cells (*109/l) | 0.40 ± 0.31 | 0.30 ± 0.25 | 0.304 | 0.25 | 0.22 | 0.578 |
| CD4+CD69+ T cells (%) | 21.1 ± 11.85 | 20.7 ± 9.4 | 0.876 | 17.4 ± 11.1 | 18.0 ± 9.7 | 0.813 |
| CD8+CD69+ T cells (*109/l) | 0.31 ± 0.46 | 0.15 ± 0.15 | 0.121 | 0.13 | 0.09 | 0.178 |
| CD8+CD69+ T cells (%) | 12.3 | 7.4 | 0.210 | 7.1 | 6.45 | 0.578 |
Mean value and standard deviation (mean ± SD); median and interquartile range (median [IQR]); p value
Pre- and postoperative cytokines (TNF-α, IL-6 and IL-10), PCT and CRP concentrations
| Preoperative | Postoperative | |||||
|---|---|---|---|---|---|---|
| IN group | C group | p | IN group | C group | p | |
| PCT (mcg/l) | 0.01 | 0.01 | 0.898 | 0.03 | 0.05 | 0.352 |
| CRP (mg/l) | 1.87 | 1.33 | 0.429 | 62.7 | 63.7 | 0.840 |
| TNF-α (ng/l) | 7.23 ± 3.23 | 8.03 ± 3.05 | 0.406 | 8.13 | 8.78 | 0.300 |
| IL-6 (ng/l) | 3.21 | 3.15 | 0.588 | 14.65 | 12.25 | 0.786 |
| IL-10 (ng/l) | 5.0 | 5.0 | 0.192 | 5.0 | 5.0 | 0.343 |
Mean value and standard deviation (mean ± SD); median and interquartile range (median [IQR]); p value